Key clinical point: First-line sunitinib therapy for mRCC may be less effective but also less toxic in real-world practice versus clinical trials.
Major finding: Median time to progression and overall survival were 5.7 months and 7.8 months, respectively; 60.9% and 8.0% of patients experienced adverse events and serious adverse events, respectively.
Study details: Multicenter African and Middle Eastern retrospective cohort study of 289 patients with mRCC started on sunitinib during 2006-2016 (OSSMAR study).
Disclosures: Dr. Ghosn disclosed that he has relationships with numerous pharmaceutical companies. The study did not receive any specific funding.
Ghosn M et al. J Glob Oncol. 2019 Oct 5. doi: 10.1200/JGO.18.00238.